Autopsy report · NCT06365619

Neoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable Melanoma

Cause of deathSlow enrollment Automatic label, confidence 0.9, unverified. How labels are made.

“Low Accrual”

The sponsor’s own words in the registry.

Life of this trial

Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status: Withdrawn
Phase: Phase 2
Sponsor: University of Utah
Sponsor type: University, hospital or other
Conditions: Melanoma
Interventions: Ipilimumab; Nivolumab
Participants: 0

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.